U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2003
181
Substance Class Protein
Created
by admin
on Wed Apr 02 01:55:31 GMT 2025
Edited
by admin
on Wed Apr 02 01:55:31 GMT 2025
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
2HLC17MX9G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AGALSIDASE ALFA (GENETICAL RECOMBINATION)
JAN  
Preferred Name English
AGALSIDASE ALFA
DASH   EMA EPAR   INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
RECOMBINANT ALPHA-GALACTOSIDASE A
Common Name English
REPLAGAL
Brand Name English
ALPHA-GALACTISIDASE
VANDF  
Common Name English
GALACTOSIDASE, .ALPHA.- (HUMAN CLONE .LAMBDA.AG18 ISOENZYME A SUBUNIT PROTEIN MOIETY REDUCED)
Common Name English
Agalsidase alfa [WHO-DD]
Common Name English
AGALSIDASE ALFA [JAN]
Common Name English
RENZY HUMAN (EC 3.2.1.22) .ALPHA.-GALACTOSIDASE (A)
Common Name English
MELIBIASE
Common Name English
Alpha-d-galactosidase [WHO-DD]
Common Name English
EC 3.2.1.22
Code English
AGALSIDASE ALFA [MI]
Common Name English
agalsidase alfa [INN]
Common Name English
AGALSIDASE ALFA (GENETICAL RECOMBINATION) [JAN]
Common Name English
AGALSIDASE ALFA [EMA EPAR]
Common Name English
AGALSIDASE ALFA [USAN]
Common Name English
.ALPHA.-D-GALACTOPYRANOSIDASE
Common Name English
ALPHA-GALACTISIDASE [VANDF]
Common Name English
.ALPHA.-D-GALACTOSIDE GALACTOHYDROLASE
Common Name English
DRX-005B
Code English
DRX005B
Code English
AGALSIDASE ALFA [MART.]
Common Name English
.ALPHA.-D-GALACTOSIDASE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29726
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
FDA ORPHAN DRUG 47190
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
EU-Orphan Drug EU/3/00/003
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
EMA ASSESSMENT REPORTS REPLAGAL (AUTHORIZED: FABRY DISEASE)
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
WHO-ATC A16AB03
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
WHO-VATC QA16AB03
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
FDA ORPHAN DRUG 601617
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
FDA ORPHAN DRUG 58691
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
FDA ORPHAN DRUG 112998
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
Code System Code Type Description
FDA UNII
2HLC17MX9G
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
LACTMED
Agalsidase Alfa
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
MERCK INDEX
m5636
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY Merck Index
USAN
LL-03
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
CAS
104138-64-9
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
GENERIC (FAMILY)
RXCUI
259351
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
NCI_THESAURUS
C74209
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
ChEMBL
CHEMBL2108214
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
CAS
9025-35-8
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
ALTERNATIVE
DRUG CENTRAL
5021
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
SMS_ID
100000092056
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
INN
8048
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
MESH
C416903
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
ECHA (EC/EINECS)
232-792-0
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
EVMPD
SUB12456MIG
Created by admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
PRIMARY
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_108
N 1_161
N 1_184
Related Record Type Details
AGALSIDASE ALFA
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
PRODUCTION SOURCE BIOLOGICAL
MOL_WEIGHT:APPROXIMATE CHEMICAL
Molecular Formula CHEMICAL
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966